The American Society of Gene & Cell Therapy (ASGCT) and Orphan Therapeutics Accelerator (OTXL), a biotech non-profit, have launched the CGTxchange, a jointly owned clearinghouse and marketplace designed to identify, evaluate and advance clinically validated cell and gene therapies (CGTs) for ultra-rare diseases that have been shelved due to commercial constraints. This will serve as…
Leaving DNA contamination at the lab bench
Cell and gene therapies are ushering in a new era of promise across a multitude of therapeutic applications, offering hope for overcoming previously insurmountable medical challenges. As a result, the sector has grown immensely, with more than 3,500 cell and gene therapies currently in development, from preclinical to pre-registration stages. Based on the current pipeline and clinical…